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RECONSTRUCTION
A series of forums to
examine the future of people
with HIV.
Forums are held from 6 to 8 p.m.

July 21 - Tuesday
Wake Up and Smell The T-cells!

July 28 - Tuesday
The Tangled Web of Public
Benefits.

August 4 - Tuesday
It's Back to Work We Go?

August 6 - Thursday
Next Steps, Where Do We Go
From Here?
Presented in the Rines Auditorium
of the Portland Public Library.
Parking validated for the Public
Market Garage, 57 Preble St.

Prevention Is Key
Says AIDS Confere nee
12th World AIDS Conference is held in Geneva, Switzerland
from The New York Times
The 12th World AIDS Conference ended on Friday, July 3, 1998 in a somber mood. A series of reports
about problems with anti-AIDS drugs and setbacks in vaccine trials left many participants thinking that their
best hope against the epidemic is the strategy they have had since it began -- prevention. But many of them
said this last hope was not being pursued as aggressively as it should be.
The mood was a sharp contrast to the euphoria at the last AIDS meeting in Vancouver, British Columbia,
two years ago. There, scientists reported that combinations of new drugs called protease inhibitors had
allowed many people infected with HIV, the AIDS virus, to leave their deathbeds, even to return to work. But
this year, the talk was of problems. Vaccine researchers gave the disheartening news that a promising
candidate vaccine, tested in monkeys, caused the disease rather than prevented it. Doctors told of patients
who failed in spite of the new drugs, or who developed side effects while taking them. And even when the
drugs offered hope, still other speakers said, it is hope beyond the reach of the vast majority of the 34 million
people now infected with the AIDS virus. Those patients cannot afford the treatment. It can cost about
$15,000 to provide the drugs to one person a year, a sum greater than the entire health budgets of many a
Third World village.
As Dr. Hoosen Coovadia, of Durban, South Africa, explained it, AIDS affects 40 percent of the children he
treats in a large black hospital there. Yet, Coovadia, who is chairman of the next World AIDS Conference in
2000 in Durban, said that he had never used any anti-HIV drugs. His hospital cannot afford them, he said.
Reports like these lead inexorably to the conclusion that the best hope for easing the epidemic is still
prevention, speakers said. Yet "over 100 times more money is being spent on therapeutics now than on the
development of prevention technologies," said Dr. Catherine Hankins, an epidemiologist at Montreal General
Hospital in Canada. Among them are chemicals that could be inserted into the vagina before sexual intercourse to kill HIV. Hankins left the meeting saying she did not feel "terribly optimistic".
Sex education, needle exchange programs, condom distribution, among other preventions, could save
millions of people from AIDS, speaker after speaker told those gathered at the meeting. At the same time,
though, many of the 13, 775 participants from 177 countries concluded that people and their government
leaders were not paying enough attention to those relatively simple steps, and that industry was doing too
little to develop more effective prevention methods.
Speakers urged that health workers combine preventions as they had drugs and adopt a communitybased approach to promote them. They called for more programs to treat sexually transmitted diseases
because those diseases can increase the risk of spreading HIV, in part by creating open sores.
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It is an interesting time to be HIV infected, from
both a global and a local perspective. The 12th World
AIDS Conference just ended about two weeks ago and
the news out of Geneva was voluminous and somber. In
a nutshell, the conclusion of the conference is that things
are not as optimistic as they seemed two years ago at the
last World AIDS Conference in Vancouver. Of course,
there was a fair amount of talk about a "cure" then, but
time spent following patients taking the protease
inhibitors has dampened spirits a bit.
Proteases were the miracle drugs that were going
to turn HIV/AIDS into a manageable, chronic disease,
so they said two years ago. It hasn't turned out that way.
There are some pretty miraculous cases of people taking
proteases who have had wonderful changes in their
health. The proteases and other drugs are working
1
onders for many. Still, many cannot tolerate the drugs,
t no benefit from the drugs, or have become resistant
the drugs. And on a global basis, the drugs are simply
t affordable to the vast majority ofinfected people.
And there are some disconcerting side effects
showing up in some people who have been on proteases
for a while now. News that heart problems, diabetes, and
disfiguring fatty lumps are showing up poses the
I dilemma, do the drugs' benefits outweigh their dangers?
"\Scientists say yes, but very cautiously.
And a couple of cases of a new drug resistant strain
of the virus is causing concern. Just as was seen after
AZT had been in use for awhile, where people were
being infected with a strain of the virus already resistant
to AZT because the carrier was resistant to AZT, so too
are there a couple of cases of people getting infected
with a strain resistant to the proteases and other widely
used drugs. What this means for those newly infected
with this strain is that they won't receive any benefit
from taking the drugs they've never even tried.
Still, all the news was not negative. Lots of
research continues on drugs, treatments, and vaccines
that may be the breakthrough we ' re all hoping for. And
now that almost everyone agrees in the importance of a
vaccine (though not which kind of vaccine) in curbing
the worldwide epidemic, greater efforts in that area will
result. And now that it is understood that the dosing
schedules are often too complicated and cumbersome

@
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for patients, efforts are in the works to make staying
drug compliant easier.
The big conclusion, though, is not really new at all.
That conclusion is the urgent importance of prevention
education. It may sound simple, but keeping people
from getting the virus is still the best hope for the future .
And with reports in this country that gay and bisexual
male youth are not as diligent in practicing safer sex as
older gay and bisexual men, prevention education is
needed more than ever. Some reports have pointed out
the success of small-group prevention education
programs, showing that prevention efforts can and do
work. The success of many needle exchange programs
was also noted as an area of prevention work that needed
more attention. The conference said that more money
and effort is needed worldwide for prevention education, particularly given the less-than-hoped-for results
with drug treatments.
Advances in the understanding of the virus continue and I've tried to include a lot of articles in this
newsletter with information from before and during the
conference which I think are ofinterest.
Locally, the Reconstruction forums have started.
They are examining what the future holds for people
with HIV who are doing well, or better than they were
doing before. And as an added bonus, the forums will
help local AIDS service organizations examine ways
they may need to change to support those clients. The
forums continue through the first week of August and I
encourage anyone interested in the future of HIV in our
area to attend. If nothing else, it is a great learning
expenence.
It is six years ago this month that Roy Keller died
of AIDS. Apart from being a very likable guy, he was the
"idea man" behind getting this newsletter from The
AIDS Project off the ground. He talked about the need
for a local newsletter for clients for long enough, that it
finally happened. Our first issue came out in December
1993, six months after his death. In hindsight, it seems
like such an obvious idea to have this newsletter, but the
obvious is often the hardest to achieve. Perhaps, that is
why Roy and his idea deserve to be remembered from
time to time.
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HIV news
AIDS Medication May Cause Buffalo Humps

C-Section May Reduce Babies' HIV Risk

Some HIV-infected people have been developing abnormal fatty deposits,
called buffalo humps and protease paunches, which may stem from the use of
protease inhibitors. While the patients lose fat and muscle from the hips and
below, as well as in their arms and faces, they add visceral fat under the
abdominal muscles and behind the neck. The FDA is worried that the drugs are
also causing an increase in risk for heart disease. Aside from the deforming fat
deposits, the drugs may cause an increase in cholesterol. Despite the
concerns, most agree that the benefits of the treatment outweigh the adverse
effects. One of the makers of protease inhibitors, Merck and Co., asserts that
there is no proof that the medication is the causative factor, noting that the fatty
deposits could be a previously unseen effect of the virus or a result of the
combination of other drugs. However, the FDA contends that the four protease
inhibitors now on the market are the primary causative suspects, and it is
currently investigating 64 case reports. One Australian study of 75 HIV-infected
subjects found that the buffalo humps are a common complication of the
treatment. Currently, researchers estimate that anywhere from 5 percent to 64
percent of HIV-infected patients may have the disfigurations to some degree.

A new study released at the international AIDS conference in Geneva,
Switzerland, indicates that delivery by Cesarean section in conjunction with
the use of AZT can almost eliminate the risk of mother-to-child vertical
transmission of HIV. Researchers found that the procedure resulted in a
transmission rate of less than a 2 percent risk of infection among 8,533 infants
born to HIV-positive mothers. Infants born vaginally to mothers who received
AZT have a 5 percent chance of infection. The C-sections were performed
before the women had begun labor. Approximately 6,000 HIV-positive women
give birth annually. About one-quarter of the children had a chance of
contracting HIV in 1994; however, short-course AZT regimens can reduce that
risk to 8 percent.

Gonorrhea Most Notifiable Infectious Disease Among U.S. Women
Gonorrhea is the most commonly identifiable infectious disease among
women 55 years and younger in almost all racial groups, according to the CDC.
Analyzed data on 48 infectious diseases among women aged 13 to 55 that
were reported to local or state health departments between 1992 and 1994
found that the 10 most common diseases, in descending order of frequency,
were gonorrhea, primary/secondary syphilis, AIDS, salmonellosis, tuberculosis, hepatitis A, hepatitis B, shigellosis, Lyme disease, and hepatitis C(non-A,
non-8).
Swaziland: AIDS Solutions
A member of the parliament of Swaziland has recommended a number of
methods to help control the spread of HIV in that nation, including the branding
or tattooing of infected individuals. Additionally, he recommended that the
country follow the example of countries like Cuba, which quarantines infected
individuals, in dealing with the virus. In response to the parliamentarian's
comments, several AIDS advocacy groups argued that the tattoos would be a
violation of human rights. Swaziland's Minister of Education suggested that all
students seeking government scholarships be required to undergo HIV testing,
noting thatthe "government is fully aware thatthis would be a very painful step
to be taken." Swaziland is among the top 10 nations in AIDS incidence.

Researchers Solve Mystery of Al DS Progression
Researchers from the CDC report that progression rates in people with HIV
are linked to co-receptor types. In some people, HIV enters host cells only
through the CCR5 receptor, while others carry viruses that can enter the host
cell through a number of receptors. A CDC biologist examined virus samples
taken from HIV-positive men at various stages of disease progression and
found that all of the rapid-progressors in the group and half of the lateprogressors had viral variations that allowed HIV to enter host cells through coreceptors other than CCR5 . The viruses in long-term non-progressors did not
show this variation.
New Drug Mix Would Simplify HIV Therapy
Researchers at the 12th World AIDS Conference in Geneva report that a new
combination drug therapy that only requires patients to take three pills a day (as
opposed to at least 10 with the now-standard AIDS "drug cocktail) has the
potential to improve patient compliance and change the way doctors treat HIV
infections. The new therapy combines once-daily Sustiva, which is expected
to be approved in the U.S. later this year, with a twice-daily pill called Combivir,
which is a combination of two older drugs, AZT and 3TC. Research has shown
the drugs to be at least as effective as therapies that include protease
inhibitors, which doctors and patients hope to replace because of significant
long-term side effects in some patients. Despite the enthusiasm by many
researchers, some have cautioned patients about the hype and point out that
even the new therapy has some drawbacks; some patients have reported
emotional problems while using the drug, and the drugs carry a potential for
birth defects.

Flat-Earth AIDS Policy

Continued Risk Behavior Among Young Gay Men in the U.S. Points to Need
for Sustained Prevention and Suggests a Focus on Social Influences

A commentary published in The Progressive asserts that it was almost
"criminal" of the Clinton administration to continue the ban on the use of federal
funds for needle-exchange programs, while endorsing the scientific data
showing that the programs are safe and effective in the reduction of the use of
shared needles, the spread of HIV, and do not increase drug use. The
Progressive notes that soon after the announcement, the Centers for Disease
Control and Prevention reported that the number of HIV infections in the United
States remain high, with women and minorities at high risk. According to some
studies, half of all people infected with HIV contracted the virus as a result of
intravenous drug use, sex with intravenous drug users, or births by intravenous
drug users. The author argues that the government is "neglecting" the public
health and that because of the administration's ban and Congress' permanent
ban on funding of needle exchanges ''thousands of people will die painful,
unnecessary deaths."

A study by the CDC shows that young gay men in the United States are more
likely to practice unsafe sex and contract HIV as compared to their older
counterparts. The study investigated sexual habits among HIV-negative gay
and bisexual men in Denver, Chicago, and San Francisco. Almost two-thirds of
the gay men reported that they had engaged in unprotected anal sex in the
previous 18 months and 56 percent of gay men aged under 25 years said that
they had engaged in unprotected receptive anal intercourse in the same time
frame. Comparatively, 46 percent of older gay men reported that they had
engaged in the same risky activity in the prior 18 months. The study found that
the increased risk habits are associated with perceived peer norms concerning
unprotected anal sex. Additionally, young gay men who socialize and meet
partners in bars were more likely to have unprotected sex. The researchers
suggested that prevention efforts focus on changing peer norms and reaching
young men in bar settings.
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HIV news
Where the Female Condom Is No Joke

Live HIV Vaccine's Safety Doubted

The female condom, manufactured by Female Health in Chicago, had a poor
debut in the United States when it was introduced in 1994, but found much
more support in the developing world. The Joint United Nations Program on
HIV/AIDS (UNAIDS) has been heavily advocating the female condom as a
method of preventing pregnancy and sexually transmitted diseases. In
addition, thanks to a volume discount negotiated by UNAIDS the cost of the
female condom went from about $2.50 to under $1 , and African nations have
purchased millions of the condoms in an effort to help control the spread of HIV.
South Africa has bought 1.5 million female condoms, while Uganda bought 1.2
million and Zambia and Zimbabwe also made significant purchases. According
to the president of Female Health, one-fifth of Botswana's sexually active
population has AIDS and the average lifespan has dropped by about 20 years.
More women than men are infected with HIV in Uganda, with the most infected
group aged 20 to 30 years old. While the female condom does not seem to be
as popular as the male condom, studies with female sex workers in Thailand
found that among women who had both options available to them, there was a
34 percent decrease in the rate of sexually transmitted diseases and a 25
percent decrease in the number of unprotected sex acts, compared to women
who only had male condoms available to them. The female condom, a
prelubricated, disposable polyurethane sheath that is inserted into the vaginal
canal prior to intercourse, allows women to control contraception without male
consent, providing another option for women with limited contraception
choices.

Researchers at the 12th AIDS Conference in Geneva presented findings of
experiments in monkeys that suggest a live attenuated AIDS vaccine may not
be possible because it provides limited protection and can lead to illness. In the
monkey experiments, the researchers said the experimental vaccine prevented
simian immunodeficiency virus (SIV) infection, the monkey equivalent of HIV, in
about half of the 15 adults vaccinated and did not provide full protection to any
of the mothers' nine offspring. The findings are similar to a study of eight
Australians infected with an HIV strain with the same missing gene, net, which
is similar to the vaccine; but several of the patients with the missing gene had a
slight decrease in CD4 levels, which suggests "something is happening,"
according to Jennifer Learmont, a nurse with the Australian Red Cross involved
in the study. Despite the concerns, the International Association of Physicians
in AIDS Care said a human study involving a vaccine was the only way to
determine the true efficacy of a live attenuated vaccine.

PCP Mutations May Explain Prophylaxis Failures
Research suggests that two amino acid mutations in Pneumocystis carinii
(PCP) may be the cause of prophylaxis failure in some patients with AIDS.
Doctors at the University of Michigan Medical Center in Ann Arbor analyzed P.
Carinii specimens from 27 patients, including 20 who had AIDS. They detected
mutations at two amino acid positions, particularly in patients who received
prophylaxis with sulfa/sulfone. The mutations appeared to be correlated with
substrate and sulfa binding and may be behind prophylaxis failure in AIDS
patients.
Toward HIV Eradication or Remission: The Tasks Ahead
Dr. David D. Ho of the Aaron Diamond AIDS Research Center at Rockefeller
University in New York City, describes the current state and future goals of
HIV/AIDS treatment and eradication. Despite the substantial declines in AIDS
incidence and mortality over the past two years, latent reservoirs of HIV cells
remain in the host body during combination therapy. Ho calculates that given
the estimated decay rate of infected memory CD4 lymphocytes, combination
therapy would have to be maintained for a minimum of five to seven years in
order to eliminate the latent reservoirs of HIV infection. Regimens lasting 10 or
more years would be required for larger reservoir sizes. Given the toxicity, cost,
and complexity of combination treatment, a regimen lasting this long is
"unacceptable," according to Ho. Increasing the decay rate while maintaining
antiretroviral therapy may be a viable strategy. Ho notes that to achieve this, it
may be required to activate the latent reservoirs. Introducing antigens or
cytokines may result in the activation of sufficient resting T cells. Many of the
activators, though, are associated with clinical toxicity. Another strategy may
be to induce remission. This could be achieved by increasing the threshold level
at which the immune system can control the HIV infection through the use of a
vaccine or through the intermittent disruption of antiretroviral therapy in order
to increase specific immune responses.

Anemia Increases Death Risk in AIDS Patients
Several studies presented at the 12th World AIDS Conference in Geneva,
indicate that untreated anemia can increase the risk of mortality in HIV and
AIDS patients. Researchers at Johns Hopkins University found that among
2,343 HIV-positive patients treated, anemia resulted in increased death rates,
even when coupled with improvements in viral load, CD4 cell count, patient
age, and opportunistic infections. Treatment of HIV with AZT has been
associated with increased incidence of anemia, which can be treated with
blood transfusions or with recombinant human erythropoetin, a drug which
boosts red-cells. Johns Hopkins' Richard Moore also cited recent data from the
Centers for Disease Control and Prevention which indicated that on average,
survival among people who had recovered from anemia was similar to that of
people who had never had the disease.
AIDS Drug Said to Combat Hepatitis B
A study published in the New England Journal of Medicine indicates that the
AIDS drug lamivudine, also called Epivir or 3TC, may slow liver damage
associated with hepatitis B virus infection. Researchers from the University of
Hong Kong examined the effects of one year of treatment in 358 patients in
China and found that inflammation signs decreased in just over 50 percent of
those receiving the medications, while only 25 percent of those receiving
placebo showed a decrease in inflammation. The drug, manufactured by Glaxo
Wellcome, inhibits reverse transcriptase, an enzyme used by both HIV and the
hepatitis B virus. Alpha interferon is the only medication currently approved for
the treatment of hepatitis B, but scientists noted that 3TC is easier to take and
may work better, although comparison studies have not been done.
First Oral Herpes Drug for HIV Patients Approved
The Food and Drug Administration has approved the use of Famvir for the
treatment of recurrent herpes in HIV-infected individuals. Many people infected
with HIV are also infected with some form of the herpes simplex virus.
Research indicates that genital herpes may be a significant factor in HIV
transmission. Famvir, manufactured by SmithKline Beecham, is the first oral
drug approved for herpes treatment in HIV-positive patients. The drug has also
been cleared for the treatment of recurrent genital herpes and shingles in HIVnegative people.

Sources for some of the material in this newsletter:

AID Atlanta, CDC Daily News Updates, Maine Bureau of Health, New York Times, Portland Press Herald, USA Today, and the Internet.
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HIV news
AIDS Groups Stunned by New York's Passage of HIV Tracking Bill
News that New York State had approved an HIV tracking bill surprised AIDS
activists, who had not expected the legislation to be passed in this session. The
measure mandates the name reporting of HIV-positive individuals to the state
and requires that government workers contact the sexual partners of those
infected. However, some advocates say the legislation will make some people
even more reluctant to be tested. According to Jeffrey L. Reynolds, of the Long
Island Association for AIDS Care, "We have enacted a law that will drive people
from testing because of the fea r of being identified in their community and the
fear of having the Health Department at your front door." Under the bill,
individuals who refuse to name their sexual partners will not be penalized and
some anonymous testing sites will be maintained.
Bill to Criminalize Knowingly Spreading of HIV Is Vetoed
Alaska Governor Tony Knowles vetoed a bill that would have made it a felony
to knowingly spread HIV. The measure, approved last month by the state
legislature, would have made it a crime to sell tainted blood or to have sex with
someone who is unaware of their partner's infected status. In explaining his
decision, Knowles said the bill "would for the first time criminalize a disease in
Alaska," noting that the state's current laws against reckless endangerment
and several forms of assault already protect its citizens.
Drug May Offer Hope for AIDS
A top AIDS researcher said Thursday that certain monoclonal antibodies,
such as Ortho Biotech's OKT3, may be effective in flushing the body of HIV that
often remains in a patient's body after treatment with drug cocktails that have
eliminated all signs of infection in some patients. Even though the infection is
not evident, experts believe HIV can hide in resting immune cells for years. In a
commentary in the journal Science , Dr. David Ho, of the Aaron Diamond AIDS
Research Center in New York, said that activators such as bacterial
superantigens or a certain class of monoclonal antibodies may be able to
stimulate the immune cells where HIV is hiding and completely flush HIV from
the body.
House Calls Help Curb TB
In Sacramento County, Calif., health officials are making house calls to
patients with tuberculosis to ensure that they take their medicine. Directly
observed treatment, short course (DOTS). has proven to be the best way to
control TB and drug resistance, which can develop when treatment regimens
are not completed. A recent study in the Journal of the American Medical
Association reported that over 90 percent of patients with tuberculosis will
complete treatment through DOTS. California recommends, but does not
require, counties to deliver and observe patients taking their drugs; currently,
about 30 percent of patients statewide do receive the therapy. Nearly 50
percent of the 115 TB patients in Sacramento County are receiving DOTS,
which is credited for the success in treating virtually all of the county's cases.
FDA Approves New Treatment for Tuberculosis
The FDA has approved the marketing of rifapentine for the treatment of TB,
marking the first new drug for the condition in more than a decade. Doctors and
researchers are applauding the new drug, which remains in the blood stream
for longer periods, allowing the number of weekly doses to be reduced by half.
The new drug should make it easier for patients to complete treatment and help
prevent the development of resistant strains. In clinical trials, one group of
patients was administered rifapentine twice weekly for two months and then
once a week for four months, while a second group was given the standard
therapy, rifampin, twice a week in the final four months; about 82 to 88 percent
of the patients in both groups were cured. In the early months of therapy,
patients in both groups were given three other tuberculosis drugs to help lower
the possibility of drug resistance.

Antiretroviral Drug Resistance Testing in Adults With HIV Infection
A panel of scientists convened by the International AIDS Society/USA Panel
has concluded that plasma HIV RNA levels and CD4 cell counts are the main
values that should be employed to determine when to start antiretroviral
therapy and subsequent changes in therapy. In addition to drug resistance as a
cause of treatment failure, the team said that adherence, drug potency, and
pharmacokinetic issues should also be reviewed.
After reviewing data from published reports and material presented at
research conferences, the team said genotypic and phenotypic testing for HIV
resistance to antiretroviral drugs may also be beneficial in managing individual
cases. In particular, emerging evidence indicates that in drug-experienced
patients, genotypic and phenotypic signs of resistance to the drug in vitro
implies poor virologic response in vivo. In these cases, resistance testing will
be beneficial in identifying drugs that will not be useful in some regimens.
However, the lack of phenotypic or genotypic evidence does not necessarily
mean that patients will respond favorably. Furthermore, the researchers said
assays that are currently being developed need to be validated and standardized, and developers need to determine a clear definition of the assays' clinical
roles. Researchers should also track the prevalence of drug resistance in
populations where the resistance is most common, especially among
antiretroviral drug-naive pregnant women or individuals with primary HIV
infection. A pattern may help physicians choose initial antiretroviral therapies
for such groups.
Public Health Implications of Antiretroviral Therapy and HIV Drug
Resistance
The widespread use of antiretroviral therapies and the rising incidence of
strains of HIV that are resistant to those therapies have opened the door to a
number of important concerns, ranging from the relationship between drug
resistance and treatment failure to public health ramifications. Among the
issues are: the frequency with which resistant strains are transmitted through
sexual contact, intravenously, or from mother to child; the ability of drugresistant strains to be transmitted; and the usefulness of antiretroviral therapy
in reducing viral levels in blood and genital fluids. The importance of patients
sticking to drug regimens is also important. As well as the relationship of
adherence to drug regimens to sustained reduction in viral load to minimize the
possibility of transmitting a drug-resistant strains through blood or genital
secretions. If the issue of preventing the development of drug-resistant strains
and the spread of such strains are not addressed, researchers expect the
possibility that drug-resistant strains can replicate will help to maintain the
epidemic and reduce the beneficial effects of antiviral therapy.
Spectrum of AIDS-Associated Malignant Disorders
New data from the AIDS-Cancer Match Study Group suggests that AIDS
results in a substantially greater risk of Hodgkin's disease, multiple myeloma,
brain cancer, and seminoma. The researchers compared the cancers of AIDS
patients to those in the general population by matching population-oriented
AIDS and cancer registries in the United States and Puerto Rico. Among the
more than 98,000 AIDS cases studied, there were 7,028 cases of Kaposi's
sarcoma, 1,793 of non-Hodgkin lymphoma (NHL), and 712 other cases of
histologically defined cancer. The incidence rates among AIDS patients were
raised 310-fold for KS, 113-fold for NHL, and 1.9-fold for all other cancers. The
authors concluded that "AIDS is associated with neoplasms already thought to
be linked to common viruses," although most of the common malignant
disorders are not specifically related to immunodeficiency.

The AIDS Project welcomes two new staff members.
Demetra Giatas has been hired as TAP's
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HIV news
Where the Female Condom Is No Joke

Live HIV Vaccine's Safety Doubted

The female condom, manufactured by Female Health in Chicago, had a poor
debut in the United States when it was introduced in 1994, but found much
more support in the developing world. The Joint United Nations Program on
HIV/AIDS (UNAIDS) has been heavily advocating the female condom as a
method of preventing pregnancy and sexually transmitted diseases. In
addition, thanks to a volume discount negotiated by UNAIDS the cost of the
female condom went from about $2.50 to under $1 , and African nations have
purchased millions of the condoms in an effort to help control the spread of HIV.
South Africa has bought 1.5 million female condoms, while Uganda bought 1.2
million and Zambia and Zimbabwe also made significant purchases. According
to the president of Female Health, one-fifth of Botswana's sexually active
population has AIDS and the average lifespan has dropped by about 20 years.
More women than men are infected with HIV in Uganda, with the most infected
group aged 20 to 30 years old. While the female condom does not seem to be
as popular as the male condom, studies with female sex workers in Thailand
found that among women who had both options available to them, there was a
34 percent decrease in the rate of sexually transmitted diseases and a 25
percent decrease in the number of unprotected sex acts, compared to women
who only had male condoms available to them. The female condom, a
prelubricated, disposable polyurethane sheath that is inserted into the vaginal
canal prior to intercourse, allows women to control contraception without male
consent, providing another option for women with limited contraception
choices.

Researchers at the 12th AIDS Conference in Geneva presented findings of
experiments in monkeys that suggest a live attenuated AIDS vaccine may not
be possible because it provides limited protection and can lead to illness. In the
monkey experiments, the researchers said the experimental vaccine prevented
simian immunodeficiency virus (SIV) infection, the monkey equivalent of HIV, in
about half of the 15 adults vaccinated and did not provide full protection to any
of the mothers' nine offspring. The findings are similar to a study of eight
Australians infected with an HIV strain with the same missing gene, net, which
is similar to the vaccine; but several of the patients with the missing gene had a
slight decrease in CD4 levels, which suggests "something is happening,"
according to Jennifer Learmont, a nurse with the Australian Red Cross involved
in the study. Despite the concerns, the International Association of Physicians
in AIDS Care said a human study involving a vaccine was the only way to
determine the true efficacy of a live attenuated vaccine.

PCP Mutations May Explain Prophylaxis Failures
Research suggests that two amino acid mutations in Pneumocystis carinii
(PCP) may be the cause of prophylaxis failure in some patients with AIDS.
Doctors at the University of Michigan Medical Center in Ann Arbor analyzed P.
Carinii specimens from 27 patients, including 20 who had AIDS. They detected
mutations at two amino acid positions, particularly in patients who received
prophylaxis with sulfa/sulfone. The mutations appeared to be correlated with
substrate and sulfa binding and may be behind prophylaxis failure in AIDS
patients.
Toward HIV Eradication or Remission: The Tasks Ahead
Dr. David D. Ho of the Aaron Diamond AIDS Research Center at Rockefeller
University in New York City, describes the current state and future goals of
HIV/AIDS treatment and eradication. Despite the substantial declines in AIDS
incidence and mortality over the past two years, latent reservoirs of HIV cells
remain in the host body during combination therapy. Ho calculates that given
the estimated decay rate of infected memory CD4 lymphocytes, combination
therapy would have to be maintained for a minimum of five to seven years in
order to eliminate the latent reservoirs of HIV infection. Regimens lasting 10 or
more years would be required for larger reservoir sizes. Given the toxicity, cost,
and complexity of combination treatment, a regimen lasting this long is
"unacceptable," according to Ho. Increasing the decay rate while maintaining
antiretroviral therapy may be a viable strategy. Ho notes that to achieve this, it
may be required to activate the latent reservoirs. Introducing antigens or
cytokines may result in the activation of sufficient resting T cells. Many of the
activators, though, are associated with clinical toxicity. Another strategy may
be to induce remission. This could be achieved by increasing the threshold level
at which the immune system can control the HIV infection through the use of a
vaccine or through the intermittent disruption of antiretroviral therapy in order
to increase specific immune responses.

Anemia Increases Death Risk in AIDS Patients
Several studies presented at the 12th World AIDS Conference in Geneva,
indicate that untreated anemia can increase the risk of mortality in HIV and
AIDS patients. Researchers at Johns Hopkins University found that among
2,343 HIV-positive patients treated, anemia resulted in increased death rates,
even when coupled with improvements in viral load, CD4 cell count, patient
age, and opportunistic infections. Treatment of HIV with AZT has been
associated with increased incidence of anemia, which can be treated with
blood transfusions or with recombinant human erythropoetin, a drug which
boosts red-cells. Johns Hopkins' Richard Moore also cited recent data from the
Centers for Disease Control and Prevention which indicated that on average,
survival among people who had recovered from anemia was similar to that of
people who had never had the disease.
AIDS Drug Said to Combat Hepatitis B
A study published in the New England Journal of Medicine indicates that the
AIDS drug lamivudine, also called Epivir or 3TC, may slow liver damage
associated with hepatitis B virus infection. Researchers from the University of
Hong Kong examined the effects of one year of treatment in 358 patients in
China and found that inflammation signs decreased in just over 50 percent of
those receiving the medications, while only 25 percent of those receiving
placebo showed a decrease in inflammation. The drug, manufactured by Glaxo
Wellcome, inhibits reverse transcriptase, an enzyme used by both HIV and the
hepatitis B virus. Alpha interferon is the only medication currently approved for
the treatment of hepatitis B, but scientists noted that 3TC is easier to take and
may work better, although comparison studies have not been done.
First Oral Herpes Drug for HIV Patients Approved
The Food and Drug Administration has approved the use of Famvir for the
treatment of recurrent herpes in HIV-infected individuals. Many people infected
with HIV are also infected with some form of the herpes simplex virus.
Research indicates that genital herpes may be a significant factor in HIV
transmission. Famvir, manufactured by SmithKline Beecham, is the first oral
drug approved for herpes treatment in HIV-positive patients. The drug has also
been cleared for the treatment of recurrent genital herpes and shingles in HIVnegative people.

Sources for some of the material in this newsletter:

AID Atlanta, CDC Daily News Updates, Maine Bureau of Health, New York Times, Portland Press Herald, USA Today, and the Internet.
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crunching the numbers: an AIDS update
AIDS in the U.S.* (from the beginning to 12/97)
641,086 cases
390,692 deaths; a death rate of 61 %
*does not include people diagnosed as HIV-positive only.

AIDS in Maine** (from the beginning to 6/98)
827 cases
439 deaths; a death rate of 53%
**includes only individuals residing in Maine at the time of their HIV
diagnosis; and does not include people diagnosed as HIV-positive only.

{), Did you know? Almost half of all AIDS diagnoses in Maine and
almost half of all deaths from AIDS in Maine have happened in the last five years.

I.,

. In Maine in the first six months o~
10 Men have been diagnosed with AIDS
Women have been diagnosed with AIDS
•
1 Child has been diagnosed with AIDS ~ -

In

aworld ol difference
~tis estimated .that HIV infects 34 million people worldwide
,·-~',:.-.

In the U.S.; the .fastest growing populations with HIV
are women and minorities.
5% of the HIV population in the U.S. is in prisons.
In the U.S., while blacks make up only 13% of its population,
they make up 57% . of new·UIV infections.

90% of all.cases i~+~urop~are in Western Europe.
Cases in.Eastern Europe went from 30,000 in 1994
to 190,000 in 1996;1
Romania has two-thirds of all cases in Eastern Europe.

":/'"

19% of the 1.3 million infected in
Latin America are female.

Thailand 'e,stimates 1 million of its population is HIV-positive.
'riln Vietnam; HIV iilfe~ .on has doubled since 1996.
'

.JI"

.

Africa, which has 10% of the world's population, has 70% ofaU cases of AIDS.
In some areas of Africa, 1 in 4 persons is infected with HIV: . , x
In Africa, people between the ages of 15 and 40 are most affected,
.
In Africa, 1t is estimated that 90% of all infected people are unaware of their HIV. status .

•
•
-

'

THE

PROJECT

Worldwide in 1997: 5.6 million people became infected with HIV.
Worldwide in 1997: 2.3 million people 'died from AIDS.
Worldwide since reporting began: 11. 7 million people have died from AIDS.
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client services
medical assistance funds
An important reminder to clients:
There are funds available to TAP clients with financial need for the following items:
Routine Dental Care. Routine Eye Care and Eyeglasses, Vitamin Supplements, NonPrescription Skin Care Products, and Non-Medicaid Medication Co-pays.
There is a dollar limit to how much a client can receive in any fiscal year. Contact your
case manager for assistance by calling TAP.

free lunch
Enjoy a free lunch at The AIDS Project every Thursday at noon. Join other clients and
TAP staff for a great meal, good conversation, and very good company. Drop on by
Thursdays at noon!

immediate seating
For free tickets to area events as they become available. sign up with Robert for
' Immediate Seating.' Robert can be contacted directly on Friday afternoons by calling
TAP at 774-6877, or you can call other times during the week and leave a message for
him with the reception person .

I.I.league
Meetings of the I. V. League support group are held on Wednesdays.
The morning group meets from 8:00 to 9:30 at Discovery House in Portland.
The evening group meets from 6:30 to 8:00 at the
Community Resource Center in Portland.
For more info, call the City of Portland
Public Health Division at 756-8257.

the meeting place
This room is used by TAP in Portland for support groups, counseling and testing, and
some client/case manager meetings. Located in Suite 632, it provides more privacy for
people served by TAP. Enter from the High Street side of the building.

tor vour information
HIV websites
Check out these websites:
www.hivpositive.com
www.thebody.com
www.projinf.org
for info on HIV and AIDS.

AIDS hoUines
Questions about HIV/AIDS?
Call toll-free
National AIDS Hotline:

1-800-342-2437
Maine AIDSline:

1-800-851-2437
Maine Teen Hotline:

1-800-851-2437
(on Wednesdays from 6-9pm)

the AIDS proiect on-line
Visit our web address at: "www.aidsproject.org'
To e-mail The AIDS Project.
send your message along to 'tap@aidsproject.org"

TAP's malling address
When writing to TAP in Portland, please send your
mail to our post office box. It really rushes mail
delivery if letters are not addressed to our street
address,
so write us at:
P. 0. Box 5305,
Portland, ME 04101

in the affirmative
In The Affirmative is a monthly newsletter published by The AIDS
Project for people living with and affected by HIV/AIDS. Letters,
articles, or other submissions should be sent to: In The Affirmative,
c/o The AIDS Project, P.O. Box 5305, Portland, ME 04101, or call
(207) 774-6877. Submissions can be printed anonymously as long
as the person submitting the material includes his or her name and
phone number for verification.
News, information, and features are as up-to-date as possible
prior to publication. Any medical information included in this
newsletter is submitted for the reader's information only, to be used
as the reader so chooses.
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TAP support groups
for people infected
and affected by HIV and AIDS

tuesdays
Time: 10:30 a.m. to noon
Group: HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP. The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.
Time: 1:00 p.m. to 2:30 p.m.
Dates: 2nd and 4th Tuesdays
Group: Women's Drop.in Support Group
A bi-weekly meeting of women living with HIV/AIDS or
directly affected by the disease (through spouse/partner,
parent, or child). Sponsored by TAP and The AIDS
Consultation Service (ACS)
at Maine Medical Center.
Location: Portland, ACS, 52 Gilman Street.
Contact Janine Collins at TAP at 774-6877
or Cindy Luce at ACS at 871-2991 for more information.
Time: 1:30 p.m. to 3:00 p.m.
Group: People living with HIV
An ongoing drop-in support group for people living with HIV.
Location: Auburn, TAP. One Auburn Center.
Contact Diana Carrigan at TAP at 783-4301 for more info.

thursdays
Time: 10:00 a.m. to 11:30 a.m.
Group: HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people
living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the corner of
Main St. (Rte. 109) and Lebanon St. (Rte. 202).
Contact Getty Payson at TAP at 985-8199 for more info.
Time: 12 noon
Group: Open Lunch for TAP Clients/Staff
An informal luncheon gathering of TAP staff and clients.
Location: Portland, TAP. Conference Room.
Contact Randy May at TAP at 77 4-6877 for more information.
Time: 5:30 p.m. to 7:00 p.m.
Group: People living with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP. The Meeting Place, Suite 632.
Contact Randy May at TAP at 774-6877 for more information.

The AIDS Project

615 Congress Street
(or 142 High Street}

P.O. Box 5305
Portl•nd. Maine 04101

Phone : 774-6877 Fax : 879--0761
AJOSline : 775-1267
or 1-800-851-2437
E-mail : tap@aidaproject.org
Website : www.aidsproject.org
Oxford/ Androscoggin Cty. Office
One Aubum Center/ Box 14L
Aubum, ME 04210
Phone : 783-4301 Fax : 795-4084
York County Office
208 Lafayette Center - Suite 5
Kennebunk, ME 04043
Phone : 985-8199 Fax: 985-8646 •51
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